Zahlavi

Understanding the effect of anti-cancer drugsmight improve cancer treatment

20. 04. 2022

An international team of scientists led by Hana Hanzlíková from the Institute of Molecular Genetics of the Czech Academy of Sciences (CAS) and Keith Caldecott from the University of Sussex in the UK has discovered which sites in the DNA molecule inside cancer cells are the basis of the effect of anticancer drugs (called PARP inhibitors). The results, published recently in the prestigious Nature Structural and Molecular Biology journal, will be used to understand the mechanism of the effect of PARP inhibitors that lead to the death of certain types of cancer cells and open the path to new ways of treating tumors.

Our body is made up of cells that need the information stored in the cell nucleus in the DNA molecule to function properly. DNA, or deoxyribonucleic acid, carries genetic information and determines proper cell division and the survival of the whole organism. Its exact copying, or replication, as well as the preservation of its integrity, must therefore be strictly controlled and quickly corrected in case of irregularities.

DNA is a double-stranded molecule, and when it is copied, two double helices are created, each with one strand from the original molecule and one complementary, newly created strand. One strand is copied simply in a straight line and a new identical whole DNA double helix is created. The other strand, however, is copied in the opposite direction in short sections, called Okazaki fragments, of which 30-50 million are produced during the copying of human DNA, i.e. during one cell division. The precise splicing of millions of DNA fragments is therefore essential for maintaining the integrity of the daughter DNA strand and the proper functioning of the cell.

Tens of thousands of fragments need to be repaired

In the past, the international team of scientists led by Hana Hanzlíková from the Institute of Molecular Genetics of the CAS and Keith Caldecott from the University of Sussex in the UK has already made the surprising discovery that although the process of connecting DNA fragments during copying is highly efficient, it is not 100% efficient. Scientists have discovered that up to tens of thousands of unlinked Okazaki fragments need to be repaired during natural cell division. The repair sites are recognised by the PARP family enzymes. These are well known to play an important role in another vital process, the repair of DNA strand breaks caused, for example, by ionising radiation. For a long time, the PARP protein has been the molecular target of a whole group of substances called PARP inhibitors, which are clinically used for the treatment of breast, ovarian, and prostate cancers. However, the nature and origin of the DNA structures on which PARP enzymes are "trapped" by these inhibitors remain unclear.

"New findings from our Czech-British research team are now showing that PARP inhibitors prevent short stretches of DNA from linking together during DNA copying in the cell and that intermediate products of unlinked Okazaki fragments are probably the main source of cytotoxicity in rapidly dividing cancer cells. The results may contribute to a better understanding of the role of PARP inhibitors in cancer treatment and help develop more effective drugs of this type," explains the team leader Hana Hanzlíková.

Obrázek zachycuje úsek dělící se molekuly DNA izolované z nádorových buněk pod elektronovým mikroskopem.  Z mateřské dvoušroubovice (P) vznikají dvě dceřiné dvouláknové molekuly DNA (D). Šipky směřují na tenčí jednovláknové  nespojené Okazakiho fragmenty na řetězci, který se kopíruje po úsecích.
The image shows a section of a dividing DNA molecule isolated from cancer cells under an electron microscope. The parental double helix (P) gives rise to two daughter double-stranded DNA molecules (D). Arrows point to thinner single-stranded unlinked Okazaki fragments on the chain, which is copied in sections.

Contacts for Media

Markéta Růžičková
Public Relations Manager
 +420 777 970 812

Eliška Zvolánková
 +420 739 535 007

Martina Spěváčková
+420 733 697 112

press@avcr.cz

Logos of the CAS for download

Annual Reports of the CAS

Press Releases